Dr Toleikis is a seasoned and experienced biotechnology executive, with over 20 years of research, intellectual property, management and business experience in the pharmacology and biotechnology sectors, the company said. His most recent position was as vice president of R&D pharmacology and drug screening for Angiotech Pharmaceuticals of Vancouver, British Columbia.
George Adams, chairman of the board of directors of Sernova, said: “Sernova is privileged to now be led by such a distinguished scientist and executive. We are fully confident that Dr Toleikis will drive our technology through the worldwide regulatory process and into commercialization. The treatment of insulin-dependent diabetes will be just the first commercial application of our platform technology.”